Buy Or Sell Opportunity • Apr 28
Now 27% undervalued after recent price drop Over the last 90 days, the stock has fallen 76% to AU$0.099. The fair value is estimated to be AU$0.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.0% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 12% in a year. Earnings are forecast to grow by 94% in the next year. New Risk • Apr 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (AU$23.8m market cap, or US$17.0m). Reported Earnings • Feb 27
First half 2026 earnings released: AU$0.011 loss per share (vs AU$0 in 1H 2025) First half 2026 results: AU$0.011 loss per share (further deteriorated from AU$0 in 1H 2025). Revenue: AU$48.0m (down 3.8% from 1H 2025). Net loss: AU$2.14m (loss widened AU$2.07m from 1H 2025). Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Aankondiging • Feb 26
SciDev Limited Revises Earnings Guidance for the Year 2026 SciDev Limited revised earnings guidance for the year 2026. For the year, the company's FY26 Revenue guidance revised to $100 million - $110 million, reflecting: Recently confirmed delay in sales opportunity for xSlik® pushed into FY27. Delays to trial conversions in Process Chemistry confirmed in February. $3 million negative impact from higher AUD:USD on forecast USD revenue. Aankondiging • Feb 23
SciDev Limited to Report First Half, 2026 Results on Feb 26, 2026 SciDev Limited announced that they will report first half, 2026 results on Feb 26, 2026 New Risk • Jan 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$81.7m market cap, or US$55.2m). New Risk • Nov 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (AU$96.9m market cap, or US$63.4m). Aankondiging • Sep 17
SciDev Limited, Annual General Meeting, Nov 20, 2025 SciDev Limited, Annual General Meeting, Nov 20, 2025. Reported Earnings • Aug 28
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: AU$0.005 loss per share (down from AU$0.011 profit in FY 2024). Revenue: AU$103.5m (down 5.3% from FY 2024). Net loss: AU$878.0k (down 140% from profit in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 7.6% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Aankondiging • Aug 25
SciDev Limited to Report Fiscal Year 2025 Results on Aug 27, 2025 SciDev Limited announced that they will report fiscal year 2025 results Pre-Market on Aug 27, 2025 Major Estimate Revision • May 08
Consensus EPS estimates fall by 27% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from AU$109.1m to AU$103.1m. EPS estimate also fell from AU$0.015 per share to AU$0.011 per share. Net income forecast to grow 66% next year vs 11% growth forecast for Chemicals industry in Australia. Consensus price target down from AU$0.65 to AU$0.60. Share price fell 2.6% to AU$0.37 over the past week. Board Change • Apr 10
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent & Non-Executive Director Dan O’Toole was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 02
First half 2025 earnings released: EPS: AU$0 (vs AU$0 in 1H 2024) First half 2025 results: EPS: AU$0 (in line with 1H 2024). Revenue: AU$49.9m (flat on 1H 2024). Net loss: AU$68.0k (down 219% from profit in 1H 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Major Estimate Revision • Jan 31
Consensus EPS estimates fall by 48% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from AU$120.6m to AU$109.1m. EPS estimate also fell from AU$0.029 per share to AU$0.015 per share. Net income forecast to grow 29% next year vs 20% growth forecast for Chemicals industry in Australia. Consensus price target down from AU$0.74 to AU$0.65. Share price fell 3.1% to AU$0.47 over the past week. Aankondiging • Nov 21
SciDev Limited Announces Resignation of Simone Watt as Director As foreshadowed at today's 2024 Annual General Meeting, SciDev Ltd. announced the resignation of Simone Watt as Director of the Company. Simone joined the SciDev Board in October of 2018. She has provided six years of steadfast support and valued insights that have played a major role in the extraordinary growth and success of the business over that time. Her deep knowledge of relevant industries and markets has been invaluable to the Board and senior leadership team. Aankondiging • Sep 27
SciDev Limited, Annual General Meeting, Nov 21, 2024 SciDev Limited, Annual General Meeting, Nov 21, 2024. Reported Earnings • Aug 28
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: EPS: AU$0.012 (up from AU$0.002 loss in FY 2023). Revenue: AU$109.2m (up 22% from FY 2023). Net income: AU$2.18m (up AU$2.51m from FY 2023). Profit margin: 2.0% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 29%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 9.3% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Price Target Changed • Apr 19
Price target increased by 29% to AU$0.54 Up from AU$0.42, the current price target is provided by 1 analyst. New target price is 42% above last closing price of AU$0.38. Stock is up 7.0% over the past year. The company is forecast to post earnings per share of AU$0.018 next year compared to a net loss per share of AU$0.0018 last year. Reported Earnings • Mar 03
First half 2024 earnings released: EPS: AU$0 (vs AU$0 in 1H 2023) First half 2024 results: EPS: AU$0 (in line with 1H 2023). Revenue: AU$50.3m (up 1.5% from 1H 2023). Net income: AU$57.0k (up 111% from 1H 2023). Profit margin: 0.1% (in line with 1H 2023). Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 46 percentage points per year, which is a significant difference in performance. Aankondiging • Sep 30
SciDev Limited, Annual General Meeting, Nov 21, 2023 SciDev Limited, Annual General Meeting, Nov 21, 2023. Agenda: To consider re-election of Directors. Reported Earnings • Aug 30
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: AU$0.002 loss per share (improved from AU$0.003 loss in FY 2022). Revenue: AU$89.9m (up 62% from FY 2022). Net loss: AU$339.0k (loss narrowed 45% from FY 2022). Revenue missed analyst estimates by 5.0%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 9.4% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings. Price Target Changed • Jul 27
Price target decreased by 7.4% to AU$0.50 Down from AU$0.54, the current price target is provided by 1 analyst. New target price is 59% above last closing price of AU$0.32. Stock is up 3.3% over the past year. The company is forecast to post earnings per share of AU$0.01 next year compared to a net loss per share of AU$0.0035 last year. Major Estimate Revision • Apr 19
Consensus EPS estimates fall by 29% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from AU$83.7m to AU$78.8m. EPS estimate also fell from AU$0.014 per share to AU$0.01 per share. Net income forecast to grow 145% next year vs 19% growth forecast for Chemicals industry in Australia. Consensus price target of AU$0.54 unchanged from last update. Share price was steady at AU$0.32 over the past week. Reported Earnings • Feb 23
First half 2023 earnings released: EPS: AU$0 (vs AU$0.014 loss in 1H 2022) First half 2023 results: EPS: AU$0 (improved from AU$0.014 loss in 1H 2022). Revenue: AU$49.6m (up 105% from 1H 2022). Net income: AU$27.0k (up AU$2.33m from 1H 2022). Profit margin: 0.1% (up from net loss in 1H 2022). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 8.5% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Nov 29
Independent & Non-Executive Director recently bought AU$80k worth of stock On the 25th of November, Dan O’Toole bought around 266k shares on-market at roughly AU$0.30 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$128k more in shares than they have sold in the last 12 months. Price Target Changed • Nov 16
Price target increased to AU$0.52 Up from AU$0.46, the current price target is provided by 1 analyst. New target price is 96% above last closing price of AU$0.27. Stock is down 55% over the past year. The company is forecast to post earnings per share of AU$0.02 next year compared to a net loss per share of AU$0.0035 last year. Aankondiging • Nov 11
SciDev Ltd Appoints Seán Halpin as Chief Executive Officer SciDev Ltd. announced the appointment of Seán Halpin as Chief Executive Officer. Seán has been serving as Interim CEO since April 2022. Seán was the Co-Founder and Commercial Director of Haldon Industries Pty Ltd. (Haldon). Post the acquisition, Seán served as the Commercial Director of Water Services for SciDev until his appointment as Interim CEO. Seán has over 15 years of experience in the engineering and environmental services sector and holds a Bachelor of Environmental Science from Dublin City University and a Masters of Science in Environmental Engineering from the University of Newcastle-upon-Tyne. The decision to appoint Sean as the permanent CEO necessitated a review of the Haldon acquisition agreement given the final outstanding earnout payment. Aankondiging • Sep 29
SciDev Limited, Annual General Meeting, Nov 15, 2022 SciDev Limited, Annual General Meeting, Nov 15, 2022. Reported Earnings • Sep 02
Full year 2022 earnings released: AU$0.003 loss per share (vs AU$0.023 profit in FY 2021) Full year 2022 results: AU$0.003 loss per share (down from AU$0.023 profit in FY 2021). Revenue: AU$56.2m (up 32% from FY 2021). Net loss: AU$616.0k (down 118% from profit in FY 2021). Over the next year, revenue is forecast to grow 21%, compared to a 21% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Price Target Changed • Apr 27
Price target decreased to AU$0.75 Down from AU$1.01, the current price target is an average from 2 analysts. New target price is 79% above last closing price of AU$0.42. Stock is down 56% over the past year. The company posted earnings per share of AU$0.023 last year. Reported Earnings • Feb 23
First half 2022 earnings: EPS exceeds analyst expectations First half 2022 results: AU$0.014 loss per share (down from AU$0.003 profit in 1H 2021). Revenue: AU$24.1m (up 32% from 1H 2021). Net loss: AU$2.30m (down AU$2.73m from profit in 1H 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 35%, compared to a 19% growth forecast for the industry in Australia. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has increased by 89% per year, which means it is tracking significantly ahead of earnings growth. Aankondiging • Dec 22
SciDev Limited Ordinary Shares to Be Deleted from Other OTC SciDev Limited Ordinary Shares will be deleted from Other OTC effective from December 22, 2021, due to Inactive Security. Executive Departure • Dec 06
Interim Chief Financial Officer Geoff Stephenson has left the company On the 6th of December, Geoff Stephenson's tenure as Interim Chief Financial Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Geoff's name. A total of 2 executives have left over the last 12 months. Price Target Changed • Nov 23
Price target decreased to AU$1.01 Down from AU$1.32, the current price target is an average from 2 analysts. New target price is 70% above last closing price of AU$0.59. Stock is down 32% over the past year. The company is forecast to post earnings per share of AU$0.015 for next year compared to AU$0.023 last year. Reported Earnings • Sep 03
Full year 2021 earnings released: EPS AU$0.023 (vs AU$0.007 loss in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$44.2m (up 145% from FY 2020). Net income: AU$3.45m (up AU$4.33m from FY 2020). Profit margin: 7.8% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 118% per year, which means it is well ahead of earnings. Board Change • Sep 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Non-Executive Director Simone Watt is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Executive Departure • Jul 13
Non-Executive Chairman Trevor Jones has left the company On the 30th of June, Trevor Jones' tenure as Non-Executive Chairman ended after 13.5 years in the role. As of March 2021, Trevor still personally held 1.20m shares (AU$511k worth at the time). Trevor is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 2.25 years. Aankondiging • May 14
SciDev Limited (ASX:SDV) completed the acquisition of Business of Haldon Industries. SciDev Limited (ASX:SDV) has entered a business sale agreement to acquire the Business of Haldon Industries for AUD 12.7 million on March 29, 2021. Under the terms of consideration, SciDev will pay upfront cash on completion of AUD1.7 million and, additionally, issue 5.4 million SciDev shares to the Haldon at issue price of AUD 0.80 per share. Share will be issued on completion with 24 month escrow. According to the performance of Haldon business in FY2021, FY2022 and FY2022 cash payment of AUD 2.4 million, AUD 2.41 million and AUD 2.41 million will be done respectively. As of December 31, 2020 Haldon reported AUD 8.13 million of revenue and generated an EBITDA of more than AUD 3 million. Sean Halpin and Jake Reardon, Founders of Haldon Industries have agreed to join SciDev and will become Directors of the operating subsidiary of SciDev that is acquiring the Haldon business. Remaining Haldon employees to join operational roles in the water segment. The completion of transaction is subject to regulatory approval: EPA licences for the mobile treatment of PFAS in NSW to pass to SciDev, customer contracts: assignment or transfer of the benefit of key customer contracts, key employees: completion is conditional on key Haldon staff entering into employment contracts with SciDev on agreed terms, assignment to SciDev of operating assets and premises leases and no materially adverse change in the business prior to completion. The transaction is expected to complete in Q4 of 2021.
SciDev Limited (ASX:SDV) completed the acquisition of Business of Haldon Industries on May 13, 2021. Aankondiging • Mar 12
SciDev Limited Maxiflox Contract with Eramet Subsidiary SLN SciDev Limited announced that it has signed a contract for supply of its MaxiFlox chemistry with SLN, a subsidiary of Eramet, the world's number one producer of ferronickel, a key raw material input to the stainless steel market. The commercial supply will begin in FY21 for SLN's Nepoui and Tiebaghi nickel operations. SciDev progressed through laboratory and field qualifications in early FY21. The Company's MaxiFlox® chemistry and OptiFlox® technology will be used onsite to improve operational efficiency and water use. Is New 90 Day High Low • Feb 19
New 90-day low: AU$0.65 The company is down 28% from its price of AU$0.90 on 20 November 2020. The Australian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$2.12 per share. Reported Earnings • Feb 10
First half 2021 earnings released: EPS AU$0.003 (vs AU$0.002 loss in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: AU$18.3m (up 200% from 1H 2020). Net income: AU$427.5k (up AU$618.7k from 1H 2020). Profit margin: 2.3% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 96% per year, which means it is well ahead of earnings. Aankondiging • Feb 09
SciDev Limited Announces Executive Changes SciDev Limited announces that as part of an ongoing Board rejuvenation process, which includes the recent appointment of independent non-executive director Dan O'Toole, Trevor Jones is resigning as Chairman of the Company after 13 years on the Board of Directors. Trevor announced his intention to retire on the 30 June 2021, or earlier should a suitable candidate be found. SciDev has engaged in a process to search for an experienced Chair. Analyst Estimate Surprise Post Earnings • Feb 09
Revenue beats expectations Revenue exceeded analyst estimates by 0.2%. Over the next year, revenue is forecast to grow 58%, compared to a 15% growth forecast for the Chemicals industry in Australia. Aankondiging • Feb 03
SciDev Limited Names Dan O'Toole BEng to the Board as an Independent, Non-Executive Director SciDev Limited announced the appointment of Dan O'Toole BEng (Hons), EngExec, FIEAust, MAusIMM, MAICD to the Board. Mr. O'Toole brings over 35 years of experience across the engineering and consulting sectors including over 18 years in executive leadership roles within Coffey International Limited and pitt&sherry. Mr. O'Toole is currently the Chairman of Viotel Limited. Prior to his current position, Mr. O'Toole was the Chief Executive Officer of pitt&sherry. Dan has been appointed as an independent, Non-Executive Director. Is New 90 Day High Low • Feb 01
New 90-day low: AU$0.70 The company is down 6.0% from its price of AU$0.75 on 03 November 2020. The Australian market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$2.16 per share. Aankondiging • Dec 23
SciDev Limited Provides an Update on the Increased Activity Levels Within the US Oil and Gas Sector SciDev Limited provided an update on the increased activity levels within the US oil and gas sector. Drilling activity continues to recover from the COVID-19 lows of the June quarter and SciDev, through HFT, is continuing to win business, gain market share and grow revenue in the sector. Recent Insider Transactions Derivative • Nov 18
MD, CEO & Executive Director exercised options and sold AU$517k worth of stock On the 16th of November, Lewis Utting exercised 800.00k options at around AU$0.10, then sold 750.00k of the shares acquired at an average of AU$0.79 per share and kept the remainder. For the year to June 2020, Lewis' total compensation was 83% salary and 17% non-salary. Since June 2020, Lewis' direct individual holding has decreased from 5.37m shares to 5.02m. Company insiders have collectively sold AU$204k more than they bought, via options and on-market transactions in the last 12 months. Is New 90 Day High Low • Nov 13
New 90-day high: AU$0.90 The company is up 28% from its price of AU$0.70 on 14 August 2020. The Australian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 7.0% over the same period. Aankondiging • Aug 17
SciDev Limited has completed a Follow-on Equity Offering in the amount of AUD 2 million. SciDev Limited has completed a Follow-on Equity Offering in the amount of AUD 2 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 3,076,923
Price\Range: AUD 0.65